These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 29705377)

  • 1. Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors.
    Ngo VTH; Hoang VH; Tran PT; Van Manh N; Ann J; Kim E; Cui M; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
    Bioorg Med Chem; 2018 Jul; 26(12):3133-3144. PubMed ID: 29705377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region.
    Ngo VTH; Hoang VH; Tran PT; Ann J; Cui M; Park G; Choi S; Lee J; Kim H; Ha HJ; Choi K; Kim YH; Lee J
    Bioorg Med Chem; 2018 Mar; 26(5):1035-1049. PubMed ID: 29398442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design.
    Hoang VH; Tran PT; Cui M; Ngo VT; Ann J; Park J; Lee J; Choi K; Cho H; Kim H; Ha HJ; Hong HS; Choi S; Kim YH; Lee J
    J Med Chem; 2017 Mar; 60(6):2573-2590. PubMed ID: 28234463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design.
    Van Manh N; Hoang VH; Ngo VTH; Ann J; Jang TH; Ha JH; Song JY; Ha HJ; Kim H; Kim YH; Lee J; Lee J
    Eur J Med Chem; 2021 Dec; 226():113819. PubMed ID: 34536669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitory effect of flavonoids on human glutaminyl cyclase.
    Li M; Dong Y; Yu X; Zou Y; Zheng Y; Bu X; Quan J; He Z; Wu H
    Bioorg Med Chem; 2016 May; 24(10):2280-6. PubMed ID: 27061673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and Evaluation of Diphenyl Conjugated Imidazole Derivatives as Potential Glutaminyl Cyclase Inhibitors for Treatment of Alzheimer's Disease.
    Li M; Dong Y; Yu X; Li Y; Zou Y; Zheng Y; He Z; Liu Z; Quan J; Bu X; Wu H
    J Med Chem; 2017 Aug; 60(15):6664-6677. PubMed ID: 28700245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of potential glutaminyl cyclase inhibitors from lead-like libraries by in silico and in vitro fragment-based screening.
    Szaszkó M; Hajdú I; Flachner B; Dobi K; Magyar C; Simon I; Lőrincz Z; Kapui Z; Pázmány T; Cseh S; Dormán G
    Mol Divers; 2017 Feb; 21(1):175-186. PubMed ID: 28070724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template.
    Tran PT; Hoang VH; Thorat SA; Kim SE; Ann J; Chang YJ; Nam DW; Song H; Mook-Jung I; Lee J; Lee J
    Bioorg Med Chem; 2013 Jul; 21(13):3821-30. PubMed ID: 23643900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.
    Coimbra JR; Sobral PJ; Santos AE; Moreira PI; Salvador JA
    Future Med Chem; 2019 Dec; 11(24):3179-3194. PubMed ID: 31838899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors.
    Xu C; Wang YN; Wu H
    J Med Chem; 2021 May; 64(10):6549-6565. PubMed ID: 34000808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing secondary glutaminyl cyclase (QC) inhibitor interactions applying an in silico-modeling/site-directed mutagenesis approach: implications for drug development.
    Koch B; Buchholz M; Wermann M; Heiser U; Schilling S; Demuth HU
    Chem Biol Drug Des; 2012 Dec; 80(6):937-46. PubMed ID: 22967026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of potent indazole-based human glutaminyl cyclase (QC) inhibitors as Anti-Alzheimer's disease agents.
    Van Manh N; Hoang VH; Ngo VTH; Kang S; Jeong JJ; Ha HJ; Kim H; Kim YH; Ann J; Lee J
    Eur J Med Chem; 2022 Dec; 244():114837. PubMed ID: 36265279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors for human glutaminyl cyclase by structure based design and bioisosteric replacement.
    Buchholz M; Hamann A; Aust S; Brandt W; Böhme L; Hoffmann T; Schilling S; Demuth HU; Heiser U
    J Med Chem; 2009 Nov; 52(22):7069-80. PubMed ID: 19863057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying hQC Inhibitors of Alzheimer's Disease by Effective Customized Pharmacophore-Based Virtual Screening, Molecular Dynamic Simulation, and Binding Free Energy Analysis.
    Lin W; Zheng X; Fang D; Zhou S; Wu W; Zheng K
    Appl Biochem Biotechnol; 2019 Apr; 187(4):1173-1192. PubMed ID: 30187344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of potential scaffolds for glutaminyl cyclase inhibitors: Virtual screening, synthesis, and evaluation.
    Zhou Q; Cai J; Qin F; Liu J; Li C; Xiong W; Wang Y; Xu C; Wu H
    Bioorg Med Chem; 2024 Jan; 97():117542. PubMed ID: 38104495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
    Chandran R; Dileep KV
    Chem Biol Drug Des; 2021 Nov; 98(5):850-856. PubMed ID: 34423556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design.
    Hoang VH; Ngo VTH; Cui M; Manh NV; Tran PT; Ann J; Ha HJ; Kim H; Choi K; Kim YH; Chang H; Macalino SJY; Lee J; Choi S; Lee J
    J Med Chem; 2019 Sep; 62(17):8011-8027. PubMed ID: 31411468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural Products from Microalgae with Potential against Alzheimer's Disease: Sulfolipids Are Potent Glutaminyl Cyclase Inhibitors.
    Hielscher-Michael S; Griehl C; Buchholz M; Demuth HU; Arnold N; Wessjohann LA
    Mar Drugs; 2016 Nov; 14(11):. PubMed ID: 27827845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease.
    Xu C; Zou H; Yu X; Xie Y; Cai J; Shang Q; Ouyang N; Wang Y; Xu P; He Z; Wu H
    ChemistryOpen; 2021 Sep; 10(9):877-881. PubMed ID: 33377311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationships of benzimidazole-based glutaminyl cyclase inhibitors featuring a heteroaryl scaffold.
    Ramsbeck D; Buchholz M; Koch B; Böhme L; Hoffmann T; Demuth HU; Heiser U
    J Med Chem; 2013 Sep; 56(17):6613-25. PubMed ID: 23886302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.